Pharmacogenomics in the treatment of lung cancer: An update

Pharmacogenomics

Volumn 16, Issue 15, 2015, Pages 1751-1760

  Morales Espinosa, Daniela ^a,b,c,d   Garciá Román, Silvia ^e   Karachaliou, Niki ^d   Rosell, Rafael ^a,d,e,f  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Fundación Clínica   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d INSTITUT UNIVERSITARI DEXEUS   (Spain)

^e Pangaea Biotech SL   (Spain)

^f Molecular Oncology Research (MORe) Foundation   (Spain)

Author keywords

DNA repair; drug metabolism; lung cancer; personalized medicine; pharmacogenomics; tailored therapy; targeted therapy

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ALK GENE; BRAF GENE; CANCER CHEMOTHERAPY; DDR2 GENE; ENT1 GENE; ERCC1 GENE; FGFR1 GENE; GENE; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROS1 GENE; RRM1 GENE; TUMOR SUPPRESSOR GENE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LUNG NEOPLASMS; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 84949207397     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.99     Document Type: Review

References (83)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015).
2. Globocan, fact sheets by cancer. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
3. Scagliotti G, Novello S. Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 42, 47-51 (2003).
4. Vogel F. Moderne probleme der humangenetik. Ergeb. Inn. Med. Kinderheilkd. 12, 52-125 (1959).
5. Meyer UA. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5, 669-676 (2004).
6. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 361, 1018-1020 (2009).
7. Huang YT, Heist RS, Chirieac LR et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J. Clin. Oncol. 27, 2660-2667 (2009).
8. Zhang Y, Martens JW, Yu JX et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res. 69, 3795-3801 (2009).
9. Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J. 12, 277-286 (2012).
10. Kratz JR, He J, Van Den Eeden SK et al. A practical molecular assay to predict survival in resected nonsquamous, non-small-cell lung cancer: development and international validation studies. Lancet 379, 823-832 (2012).
11. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 299, 1335-1344 (2008).
12. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166-176 (2010).
13. Tang S, Pan Y, Wang Y et al. Genome-wide association study of survival in early-stage non-small cell lung cancer. Ann. Surg. Oncol. 22, 630-635 (2014).
14. Han JY, Lee YS, Shin ES et al. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy. Pharmacogenomics J. 14, 20-27 (2013).
15. Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel).,3, 1351-1371 (2011).
16. Long DF, Repta AJ. Cisplatin: chemistry, distribution and biotransformation. Biopharm. Drug Dispos. 2, 1-16 (1981).
17. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
18. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991 (2006).
19. Bepler G, Williams C, Schell MJ et al. Randomized International Phase III Trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 31, 2404-2412 (2013).
20. Wislez M, Barlesi F, Besse B et al. Customized adjuvant Phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J. Clin. Oncol. 32, 1256-1261 (2014).
21. Tibaldi C1, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14, 1797-1803 (2008).
22. Sigmond J, Backus HH, Wouters D et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem. Pharmacol. 66, 431-438 (2003).
23. Zhou C, Ren S, Zhou S et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn. J. Clin. Oncol. 40, 954-960 (2010).
24. Matullo G, Palli D, Peluso M et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22, 1437-1445 (2001).
25. Britten CD, Izbicka E, Hilsenbeck S et al. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother. Pharmacol. 44, 105-110 (1999).
26. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008).
27. Tanaka F, Wada H, Fukui Y, Fukushima M. Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann. Oncol. 22, 1791-1797 (2011).
28. Wang L, Wang R, Pan Y, Sun Y, Zhang J, Chen H. The pemetrexed-containing treatments in the non-small cell lung cancer is-/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. BMC Cancer 14, 205 (2014).
29. Chang MH, Ahn JS, Lee J et al. The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 69, 323-329 (2010).
30. Sun JM, Ahn JS, Jung SH et al. Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylated synthase expression in nonsquamous non-small-cell lung cancer: a biomarker-stratified randomized Phase II trial. J. Clin. Oncol. 33(22), 2450-2456 (2015).
31. Tiseo M, Giovannetti E, Tibaldi C et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78, 92-99 (2012).
32. Krawczyk P, Kucharczyk T, Kowalski DM et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J. Cancer Res. Clin. Oncol. 140, 2047-2057 (2014).
33. Smit EF, Socinski MA, Mullaney BP et al. Biomarker analysis in a Phase III study of pemetrexed-carboplatin versus etoposidecarboplatin in chemonaive patients with extensive-stage smallcell lung cancer. Ann. Oncol. 23, 1723-1729 (2012).
34. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 95, 753-757 (2004).
35. Oguri T, Achiwa H, Muramatsu H et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 256, 112-119 (2007).
36. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318-1325 (2004).
37. Rosell R. Pharmacogenomics and gemcitabine. Ann. Oncol. 17, v13-v16 (2006).
38. Dong X, Hao Y, Wei Y, Yin Q, Du J, Zhao X. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS ONE 9, e92320 (2014).
39. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 41, 77-88 (2009).
40. Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25, 32-42 (2007).
41. Gilbert JA, Salavaggione OE, Ji Y et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12, 1794-1803 (2006).
42. Joerger M, Burgers JA, Baas P et al. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother. Pharmacol. 69, 25-33 (2012).
43. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res. 16, 320-329 (2010).
44. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-667 (1979).
45. Yared JA, Tkaczuk KHR. Update on taxane development: new analogs and new formulations. Drug Des. Devel. Ther. 6, 371-384 (2012).
46. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360, 1007-1014 (2002).
47. Taron M1, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 13, 2443-2449 (2004).
48. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 4, e5133 (2009).
49. Moran T, Cobo M, Domine M et al. Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized Phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECPBREC). ASCO Meet. Abstr. 31, LBA8002 (2013).
50. Zhao HY, Huang H, Hu ZH et al. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. Anticancer Drugs 23, 534-542 (2012).
51. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
52. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
53. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
54. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 41(Suppl. 1), S29-S42 (2003).
55. Kurie JM, Shin HJ, Lee JS et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin. Cancer Res. 2, 1787-1793 (1996).
56. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 29, 3-14 (2002).
57. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
58. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
59. Yang JC, Hirsh V, Schuler M et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013).
60. Ninomiya T, Takigawa N, Ichihara E et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol. Cancer Ther. 12, 589-597 (2013).
61. Costa C, Molina MA, Drozdowskyj A et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized Phase III EURTAC trial. Clin. Cancer Res. 20, 2001-2010 (2014).
62. Sequist LV, Soria JC, Goldman JW et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1700-1709 (2015).
63. Jänne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689-1699 (2015).
64. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
65. Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378-381 (2012).
66. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1 study. Lancet Oncol. 13, 1011-1019 (2012).
67. Kim DW, Ahn MJ, Shi Y et al. Results of a global Phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 30, 7533 (2012).
68. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
69. Zhong L1, Peng X, Hidalgo GE et al. Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect. Prev. 27, 285-290 (2003).
70. Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. J. Thorac. Oncol. 3, S152-S159 (2008).
71. Pillai RN, Ramalingam SS. Heat shock protein 90 inhibitors in non-small-cell lung cancer. Curr. Opin. Oncol. 26, 159-164 (2014).
72. Ou SHI, Bang YJ, Camidge DR et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 31, 8032 (2013).
73. Scheffler M, Schultheis A, Teixido C et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 6, 10577-10585 (2015).
74. Weiss J, Sos ML, Seidel D et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2, 62ra93 (2010).
75. Hammerman PS, Sos ML, Ramos AH et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1, 78-89 (2011).
76. Reis-Filho JS, Simpson PT, Turner NC et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12, 6652-6662 (2006).
77. Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085-2094 (2010).
78. Wu YM, Su F, Kalyana-Sundaram S et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636-647 (2013).
79. Search of: FGFR1 NSCLC-list results-ClinicalTrials.gov www.clinicaltrials.gov/ct2/resultsterm
80. Chen D, Zhang LQ, Huang JF et al. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 9, e101354 (2014).
81. Marchetti A, Felicioni L, Malatesta S et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 29, 3574-3579 (2011).
82. Cardarella S, Ogino A, Nishino M et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin. Cancer Res. 19, 4532-4540 (2013).
83. Haura EB, Tanvetyanon T, Chiappori A et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1387-1394 (2010).